GlassScriptPhysician profile
Michel Bidros
NPI 1609036227
$7,389.98
in general payments reported to CMS, 2019-2025
45 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,511 · 2020: $946 · 2021: $1,002 · 2022: $825 · 2023: $1,421 · 2024: $305 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.16 |
| Education | $138.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $830.91 | 2019-2023 | Lumakras, Kyprolis |
| Incyte Corporation | $684.10 | 2019-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $508.87 | 2020-2024 | Imfinzi, Calquence |
| Jazz Pharmaceuticals INC. | $462.59 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $432.52 | 2019-2024 | Opdivo |
| Janssen Biotech, INC. | $426.16 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $387.88 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $387.65 | 2019-2025 | |
| Eisai INC. | $325.38 | 2019-2022 | |
| Celgene Corporation | $291.37 | 2019-2023 | Reblozyl |
| Pfizer INC. | $235.91 | 2019-2025 | |
| Seagen INC. | $217.85 | 2022-2025 | Tukysa, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $189.98 | 2019-2023 | Imbruvica |
| Daiichi Sankyo INC. | $183.53 | 2019-2024 | Injectafer |
| Genzyme Corporation | $166.09 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Bidros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.